Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering. Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson's disease and for general corporate purposes. About Gain Therapeutics, Inc. Gain's unique approach enables the discovery of novel, allosteric small molecule modulators that can resto ...

Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson's disease and for general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The securities de ...

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ("Gain" or the "Company") (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre-funded warrants offered in the offering. All of the securities are being offered ...

Core Insights - Gain Therapeutics, Inc. announced that a late-breaking abstract on its drug candidate GT-02287 has been accepted for presentation at the FENS Forum 2024, highlighting cognitive performance improvements in a preclinical model of GBA1 Parkinson's disease [1][2] Company Overview - Gain Therapeutics is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies [6] - The lead drug candidate, GT-02287, is designed to treat GBA1 Parkinson's disease and is currently in a Phase 1 clinical trial [6] Drug Candidate Details - GT-02287 is an orally administered, brain-penetrant small molecule that acts as an allosteric protein modulator, restoring the function of the lysosomal enzyme glucocerebrosidase (GCase) [4] - In preclinical models, GT-02287 has shown to restore GCase function, reduce aggregated α-synuclein, decrease neuroinflammation and neuronal death, increase dopamine levels, and improve both motor function and cognitive performance [4] - The drug also significantly reduced plasma neurofilament light chain (NfL) levels, which is an emerging biomarker for neurodegeneration [4] Funding and Support - Gain Therapeutics has received funding support from The Michael J. Fox Foundation for Parkinson's Research, The Silverstein Foundation for Parkinson's with GBA, and the Eurostars-2 joint program co-funded by the European Union Horizon 2020 research and Innosuisse [5] Research and Development Platform - The company utilizes its Magellan™ drug discovery platform, which leverages AI-supported structural biology and supercomputer-powered models to identify novel allosteric binding sites on disease-implicated proteins [7] - This platform enhances the original SEE-Tx® platform, allowing access to vast chemical spaces of over five trillion compounds for drug discovery [7][8]

Core Insights - Gain Therapeutics, Inc. announced that a late-breaking abstract on GT-02287 has been accepted for presentation at the FENS Forum 2024, highlighting cognitive performance improvements in a preclinical model of GBA1 Parkinson's disease [1][2] Company Overview - Gain Therapeutics is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies [6] - The lead drug candidate, GT-02287, is in clinical development for GBA1 Parkinson's disease and is currently undergoing a Phase 1 clinical trial [6] Drug Candidate Details - GT-02287 is an orally administered, brain-penetrant small molecule that acts as an allosteric protein modulator, restoring the function of the lysosomal enzyme glucocerebrosidase (GCase) impaired by GBA1 gene mutations [4] - In preclinical models, GT-02287 has shown to restore GCase function, reduce aggregated α-synuclein, decrease neuroinflammation and neuronal death, increase dopamine levels, and improve both motor function and cognitive performance [4] - The drug also significantly reduced plasma neurofilament light chain (NfL) levels, a biomarker for neurodegeneration [4] Funding and Support - Gain Therapeutics has received funding support from The Michael J. Fox Foundation for Parkinson's Research, The Silverstein Foundation for Parkinson's with GBA, and the Eurostars-2 joint program co-funded by the European Union Horizon 2020 research and Innosuisse [5] Research and Development Platform - The company utilizes the Magellan™ drug discovery platform, which leverages AI-supported structural biology and supercomputer-powered models to identify novel allosteric binding sites on disease-implicated proteins [7] - This platform enhances the original SEE-Tx® platform with new AI and machine-learning tools, allowing access to a vast chemical space of over five trillion compounds [7][8] Event Details - The poster presentation at the FENS Forum will take place on June 27, 2024, at 11:30 am, focusing on the improvements in daily living activities and cognitive performance due to GT-02287 [2]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40237 GAIN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 85-1726310 (Sta ...

Exhibit 99.1 Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update BETHESDA, Md., May 14, 2024 – Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended March 31, 2024, and provides a corporate update. Corporate Highlights from Q1 2024 to Date "Gain continues to b ...

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces positive results from the single ascending dose (SAD) part of its Phase 1 study. GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events. The good safety and tolerability ...

Shares of Gain Therapeutics, Inc. (GANX) have been struggling lately and have lost 6.5% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the f ...

A downtrend has been apparent in Gain Therapeutics, Inc. (GANX) lately with too much selling pressure. The stock has declined 25.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical ind ...